Our HTGF Portfolio of startups offers excellent opportunities and is always hiring talented people.
Tacalyx is a biotech company that develops therapies that target cancer by focusing on tumor-associated carbohydrate antigens, which are specific sugar structures found on the surface of cancer cells. The company builds antibody-based therapeutics designed to selectively bind to these antigens, enabling targeted delivery of treatments while minimizing impact on healthy tissues. Its platform is centered on generating high-affinity antibodies against these glycan structures, which have historically been difficult to target, allowing the development of modalities such as antibody-drug conjugates, T cell engagers, and multispecific antibodies. These therapies are designed to address solid tumors, including cancers that lack effective treatment options or show resistance to existing therapies.